CN1045961C - 制备协同组合物及协同药物制剂的方法 - Google Patents

制备协同组合物及协同药物制剂的方法 Download PDF

Info

Publication number
CN1045961C
CN1045961C CN92104553A CN92104553A CN1045961C CN 1045961 C CN1045961 C CN 1045961C CN 92104553 A CN92104553 A CN 92104553A CN 92104553 A CN92104553 A CN 92104553A CN 1045961 C CN1045961 C CN 1045961C
Authority
CN
China
Prior art keywords
ester
compound
salt
pharmaceutically acceptable
oxathiolane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN92104553A
Other languages
English (en)
Chinese (zh)
Other versions
CN1068570A (zh
Inventor
J·M·卡梅伦
N·坎马克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GLAXO
Glaxo Group Ltd
Original Assignee
GLAXO
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27265656&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1045961(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB919110624A external-priority patent/GB9110624D0/en
Priority claimed from GB919121381A external-priority patent/GB9121381D0/en
Priority claimed from GB919123581A external-priority patent/GB9123581D0/en
Application filed by GLAXO filed Critical GLAXO
Publication of CN1068570A publication Critical patent/CN1068570A/zh
Application granted granted Critical
Publication of CN1045961C publication Critical patent/CN1045961C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN92104553A 1991-05-16 1992-05-15 制备协同组合物及协同药物制剂的方法 Expired - Lifetime CN1045961C (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB919110624A GB9110624D0 (en) 1991-05-16 1991-05-16 Combinations
GB9110624.5 1991-05-16
GB9121381.9 1991-10-08
GB919121381A GB9121381D0 (en) 1991-10-08 1991-10-08 Combinations
GB9123581.2 1991-11-06
GB919123581A GB9123581D0 (en) 1991-11-06 1991-11-06 Combinations

Publications (2)

Publication Number Publication Date
CN1068570A CN1068570A (zh) 1993-02-03
CN1045961C true CN1045961C (zh) 1999-10-27

Family

ID=27265656

Family Applications (1)

Application Number Title Priority Date Filing Date
CN92104553A Expired - Lifetime CN1045961C (zh) 1991-05-16 1992-05-15 制备协同组合物及协同药物制剂的方法

Country Status (25)

Country Link
US (2) US5627186A (enExample)
EP (1) EP0513917B2 (enExample)
JP (1) JP2868671B2 (enExample)
KR (1) KR100246687B1 (enExample)
CN (1) CN1045961C (enExample)
AT (1) ATE131730T1 (enExample)
AU (2) AU1787492A (enExample)
CA (1) CA2068790C (enExample)
CZ (1) CZ285232B6 (enExample)
DE (2) DE69206876T3 (enExample)
DK (1) DK0513917T4 (enExample)
ES (1) ES2083668T5 (enExample)
GR (1) GR3018915T3 (enExample)
HK (1) HK78897A (enExample)
IE (1) IE73261B1 (enExample)
IL (1) IL101883A (enExample)
LU (1) LU90234I2 (enExample)
MX (1) MX9202279A (enExample)
NL (1) NL980018I2 (enExample)
NO (2) NO301690B1 (enExample)
NZ (2) NZ242754A (enExample)
OA (1) OA10058A (enExample)
SK (1) SK279262B6 (enExample)
TW (1) TW273550B (enExample)
WO (1) WO1992020344A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US6812233B1 (en) 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
WO1993023021A2 (en) * 1992-05-13 1993-11-25 The Wellcome Foundation Limited Therapeutic combinations
US6177435B1 (en) 1992-05-13 2001-01-23 Glaxo Wellcome Inc. Therapeutic combinations
GB9215178D0 (en) * 1992-07-16 1992-08-26 Glaxo Group Ltd Antiviral combinations
IL113432A (en) 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
FR2720397B1 (fr) * 1994-05-24 1996-08-23 Laphal Laboratoires Sa Nouveaux oxathiolanes, leur procédé de préparation et les compositions pharmaceutiques qui en renferment.
TW401303B (en) * 1994-07-01 2000-08-11 Janssen Pharmaceutica Nv Anti-HIV triple combination
GB9503850D0 (en) * 1995-02-25 1995-04-19 Glaxo Group Ltd Medicaments
MY115461A (en) * 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
JP2000515852A (ja) 1996-06-25 2000-11-28 グラクソ、グループ、リミテッド Ｈｉｖの治療に使用するためのｖｘ４７８、ジドブジン、ｆｔｃおよび／または３ｔｃを含んでなる組合わせ
US6113920A (en) * 1996-10-31 2000-09-05 Glaxo Wellcome Inc. Pharmaceutical compositions
GB9622681D0 (en) * 1996-10-31 1997-01-08 Glaxo Group Ltd Pharmaceutical compositions
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
DE69840216D1 (de) 1997-08-08 2008-12-24 Celmed Oncology Usa Inc Verfahren und Zubereitungen um Resistenz gegen biologische oder chemische Therapien zu Überwinden
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
ES2172303T3 (es) 1998-01-23 2002-09-16 Newbiotics Inc Agentes terapeuticos obtenidos por catalisis enzimatica.
AU4716299A (en) * 1998-06-24 2000-01-10 Emory University Use of 3'-azido-2',3'-dideoxyuridine in combination with further anti-hiv drugs for the manufacture of a medicament for the treatment of hiv
IL147749A0 (en) 1999-07-22 2002-08-14 Newbiotics Inc Methods for treating therapy-resistant tumors
US6432966B2 (en) 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
AP2220A (en) * 2001-05-11 2011-03-24 Cipla Medpro Pty Ltd Pharmaceutical composition.
ATE361059T1 (de) * 2002-11-08 2007-05-15 Glaxo Group Ltd Antivirale zusammensetzungen
JP4996241B2 (ja) 2003-01-14 2012-08-08 ギリアード サイエンシーズ， インコーポレイテッド 組み合わせ抗ウイルス治療のための組成物および方法
AU2003242405A1 (en) 2003-05-22 2004-12-13 Lead Chemical Co., Ltd. Compounds and preparaitons having antiviral effect
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
RU2331420C2 (ru) * 2005-12-08 2008-08-20 Роберт Шалвович Бибилашвили Противовирусное средство (варианты) и способ лечения на его основе
EP1975923B1 (en) * 2007-03-28 2016-04-27 Nuance Communications, Inc. Multilingual non-native speech recognition
WO2010137027A1 (en) 2009-05-27 2010-12-02 Hetero Research Foundation Solid oral dosage forms of lamivudine
CN114010776A (zh) 2010-06-09 2022-02-08 疫苗技术股份有限公司 用于增强抗逆转录病毒治疗的hiv感染者的治疗性免疫
CA2866133A1 (en) 2012-03-05 2013-09-12 Cipla Limited Pharmaceutical antiretroviral combinations comprising lamivudine, festinavir and nevirapine

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1214611B (it) * 1985-05-22 1990-01-18 Schiena Ricerche Composti per uso cosmetico dermatologico e relative composizioni.
GB8717955D0 (en) * 1987-07-29 1987-09-03 Fujisawa Pharmaceutical Co Prevention & treatment of aids
US5270464A (en) * 1989-03-14 1993-12-14 Janssen Pharmaceutica N.V. Anti-HIV-1 tetrahydroimidazo[1,4]benzodiazepin-2-(thi) ones
EP0362359A4 (en) * 1988-03-23 1991-11-21 New York University Antiviral composition containing aromatic polycyclic diones and nucleoside analogs and method for treating retrovirus infections
JPH02504283A (ja) * 1988-03-23 1990-12-06 ニューヨーク　ユニバーシィティ 芳香族多環式ジオン化合物とヌクレオシド類似化合物とを含む抗ウイルス性組成物及びレトロウイルス感染を治療するための方法
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
ES2038847T3 (es) * 1988-09-28 1993-08-01 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Proceso para la preparacion de una composicion farmacutica conteniendo zidovudine e inosiplex para el tratamiento del sida y sindromes afines.
DE58902899D1 (de) * 1988-12-14 1993-01-14 Ciba Geigy Ag 2',3'-dideoxypurinnucleosid/purinnucleosid-phosphorylase-inhibitor kombinationstherapie und zusammensetzungen dafuer.
US5132291A (en) * 1989-01-24 1992-07-21 Gensia Pharmaceuticals, Inc. Antivirals and methods for increasing the antiviral activity of azt
IL93136A (en) * 1989-02-23 1995-01-24 Janssen Pharmaceutica Nv Tetrahydroimidazo (1,4) benzodiazepin-2-thione derivatives, their preparation and pharmaceutical compositions containing them
GR1000618B (el) * 1989-03-17 1992-08-31 Oncogen Μεθοδος αναστολης hiv χρησιμοποιωντας συνεργιστικους συνδυασμους νουκλεοσιδικων παραγωγων.
US5011829A (en) * 1989-06-02 1991-04-30 G. D. Searle & Co. Pharmaceutical composition and method of inhibiting virus
SE464168B (sv) † 1989-07-19 1991-03-18 Bo Fredrik Oeberg Antiviral komposition bestaaende av en 3'-fluoro-2',3'-dideoxynukleosidfoerening och en 2',3'-dideoxynukleosidfoerening (exempelvis azt)
US5116823A (en) * 1990-02-27 1992-05-26 Roger Williams General Hospital Drug combinations containing AZT
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination

Also Published As

Publication number Publication date
EP0513917A1 (en) 1992-11-19
CA2068790A1 (en) 1992-11-17
SK119993A3 (en) 1994-04-06
AU661307B2 (en) 1995-07-20
DE69206876T2 (de) 1996-05-23
NO1999018I1 (no) 1999-07-22
NL980018I2 (nl) 1998-11-02
GR3018915T3 (en) 1996-05-31
CZ242893A3 (en) 1994-07-13
CN1068570A (zh) 1993-02-03
WO1992020344A1 (en) 1992-11-26
DE69206876D1 (de) 1996-02-01
EP0513917B2 (en) 2001-03-07
JPH06234641A (ja) 1994-08-23
IE73261B1 (en) 1997-05-21
TW273550B (enExample) 1996-04-01
LU90234I2 (fr) 1998-06-24
IL101883A0 (en) 1992-12-30
AU1627992A (en) 1992-11-19
US5627186A (en) 1997-05-06
CA2068790C (en) 2005-06-07
DE19875016I2 (de) 2004-07-01
ATE131730T1 (de) 1996-01-15
NZ242754A (en) 1996-11-26
CZ285232B6 (cs) 1999-06-16
OA10058A (en) 1996-10-14
US5859021A (en) 1999-01-12
IE921566A1 (en) 1992-11-18
DE69206876T3 (de) 2004-08-12
KR100246687B1 (ko) 2000-04-01
NO921947L (no) 1992-11-17
NO921947D0 (no) 1992-05-15
SK279262B6 (sk) 1998-08-05
NO301690B1 (no) 1997-12-01
DK0513917T4 (da) 2001-06-25
IL101883A (en) 1998-10-30
MX9202279A (es) 1992-11-01
JP2868671B2 (ja) 1999-03-10
NZ299240A (en) 2004-11-26
EP0513917B1 (en) 1995-12-20
KR920021148A (ko) 1992-12-18
ES2083668T3 (es) 1996-04-16
AU1787492A (en) 1992-12-30
HK78897A (en) 1997-06-20
DK0513917T3 (da) 1996-02-05
ES2083668T5 (es) 2001-06-16
NL980018I1 (nl) 1998-07-01

Similar Documents

Publication Publication Date Title
CN1045961C (zh) 制备协同组合物及协同药物制剂的方法
ES2224547T3 (es) Actividad antiviral y resolucion del 2-hidroximetil-5-(5-fluorocitosin-1-il)-1,3-oxatiolano.
CN100542535C (zh) 含有1,3-氧硫杂环戊烷核苷类似物的药物组合物的制备方法
KR960007532B1 (ko) 1,3-옥사티오란 뉴클레오시드 동족체
JPH10507772A (ja) Ｌ−リボフラノシルヌクレオシド
MC1742A1 (fr) Procede pour preparer un derive de 3'-azido-3'desoxythymigline et procede pour preparer une formulation pharmaceutique le contenant
WO2016155593A1 (zh) 4'-硫代核苷的新型化合物及其制备方法、药物组合物和应用
CN101189249A (zh) 膦酰基-戊-2-烯-1-基核苷和类似物
CN104086612A (zh) 4-取代胺基-2′-脱氧-2′-氟-4′-叠氮-β-D-胞苷类核苷化合物、制备方法及其应用
CN108517033A (zh) 一种新型双重脑靶向脂质材料及其在药物传递系统的应用
ES2777326T3 (es) Enantiómeros del 1',6'-isómero de la neplanocina A
US5672594A (en) L-erythrosyl nucleosides
JPH07502740A (ja) 治療用ヌクレオシド
Leggio et al. A novel class of 4′-aza analogues of 2′, 3′-dideoxynucleosides as potential anti-HIV drugs
CN117417355A (zh) 稠杂环类化合物及其制备方法与用途
CN110981888B (zh) N-芳基二硫吡咯酮脲类和氨基酯类衍生物及其制备和应用
RU2418795C2 (ru) Производные диоксолана для лечения рака
CN1324034C (zh) 具有释放NO功能的噁二唑并[3,4－d]嘧啶苷类化合物及其药学上的用途
US3775398A (en) N-oxide of double stranded rna
RU2139059C1 (ru) Противовирусная комбинация, содержащая нуклеозидный аналог, фармацевтическая композиция, способ лечения
DRISCOLL Activated Prodrugs Designed for the Treatment of Human Immunodeficiency Virus in the Central Nervous System
CN101891752A (zh) Dck类似物的前药及其制备方法和用途
JPS63267723A (ja) 抗腫瘍剤
CA2203675A1 (en) L-erythrosyl nucleosides

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C15 Extension of patent right duration from 15 to 20 years for appl. with date before 31.12.1992 and still valid on 11.12.2001 (patent law change 1993)
OR01 Other related matters
C17 Cessation of patent right
CX01 Expiry of patent term

Expiration termination date: 20120515

Granted publication date: 19991027